Meropenem/vaborbactam

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

Retrieved on: 
Tuesday, September 20, 2022

Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem(meropenem and vaborbactam) in the People's Republic of China (China).

Key Points: 
  • Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem(meropenem and vaborbactam) in the People's Republic of China (China).
  • This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enterobacterales (CRE).
  • According to China Antimicrobial Surveillance Network (CHINET), theincidence ofcarbapenem-resistantKlebsiella pneumoniae (CRKP) infections has experienced a steep increase in the last 10 years.
  • "We are excited to partner with Menarini to develop and commercialize Vaboremin China and bring better treatment options to patients with severe ailments.

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

Retrieved on: 
Tuesday, September 20, 2022

Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China).

Key Points: 
  • Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China).
  • This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enterobacterales (CRE).
  • According to China Antimicrobial Surveillance Network (CHINET), theincidence ofcarbapenem-resistantKlebsiella pneumoniae (CRKP) infections has experienced a steep increase in the last 10 years.
  • "We are excited to partner with Menarini to develop and commercialize Vaborem in China and bring better treatment options to patients with severe ailments.

Global $13.8 Billion Antimicrobial Resistance Market, 2027 | Opportunity Breakdown by Disease, Pathogen, Drug Class, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, September 27, 2021

The global antimicrobial resistance market was valued at US$ 9.39 billion in 2020, and is estimated to reach US$ 13.8 billion in 2027, with a CAGR of 4.68% from 2021-2027.

Key Points: 
  • The global antimicrobial resistance market was valued at US$ 9.39 billion in 2020, and is estimated to reach US$ 13.8 billion in 2027, with a CAGR of 4.68% from 2021-2027.
  • The emergence and spread of drug-resistant pathogens which have acquired new resistance mechanisms, leading to antimicrobial resistance, continues to threaten our ability to treat common infections.
  • New antibacterial are urgently needed - for instance, to treat carbapenem-resistant gram-negative bacterial infections as identified in the WHO priority pathogen list.
  • Europe was the second largest regional market in the global arena in 2020, supported largely by growing number of antibiotic-resistant infections.

Melinta Therapeutics Successfully Completes Financial Restructuring

Retrieved on: 
Monday, April 20, 2020

Commercial-stage antibiotics company Melinta Therapeutics (Melinta) and healthcare investment firm Deerfield Management Company, L.P. (Deerfield), announced today that Melinta has successfully completed its financial restructuring and has emerged from Chapter 11.

Key Points: 
  • Commercial-stage antibiotics company Melinta Therapeutics (Melinta) and healthcare investment firm Deerfield Management Company, L.P. (Deerfield), announced today that Melinta has successfully completed its financial restructuring and has emerged from Chapter 11.
  • Melinta will continue to actively supply, distribute, and support its four marketed products for the treatment of certain antibiotic-resistant infections: Vabomere (meropenem and vaborbactam), Orbactiv (oritavancin), Minocin (minocycline) for Injection and Baxdela (delafloxacin).
  • In addition, with its new, solid financial footing, Melinta expects to enhance its portfolio with the addition of new commercial and clinical-stage pipeline candidates in support of its mission of serving the critical needs of patients in the hospital and hospital ecosystem.
  • The Melinta team has demonstrated an ability to successfully deliver important antibiotics to treat serious infections and has shown resilience and dedication during the most challenging of times, said Deerfield Partner Jonathan Leff.